|
|
|
|
|
|
Sponsored by: |
Novo Nordisk |
Information provided by: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00675493 |
This trial is conducted in Europe.
The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clinical practice conditions in Romania.
Condition | Intervention |
Diabetes Mellitus |
Drug: biphasic insulin aspart 30 |
MedlinePlus related topics: | Diabetes |
Drug Information available for: | Insulin Insulin aspart |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Evaluation of Glycaemic Control of NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Type 1 and Type 2 Diabetes Mellitus. |
Estimated Enrollment: | 1000 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
A |
Drug: biphasic insulin aspart 30
Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
|
Ages Eligible for Study: | 10 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Type 1 and type 2 diabetes patients inadequately controlled on human premixes
Inclusion Criteria:
Exclusion Criteria:
Clinical Trials at Novo Nordisk 
  |
Responsible Party: | Novo Nordisk A/S ( Public Access to Clinical Trials ) |
Study ID Numbers: | BIASP-3567 |
First Received: | May 7, 2008 |
Last Updated: | July 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00675493 |
Health Authority: | Romania: National Medicines Agency |
|
|
|